Contrast Media Market worth $12.08 billion by 2031 | MarketsandMarkets™

17.03.2026

DELRAY BEACH, Fla., March 17, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Contrast Media Market is projected to grow from about USD 7.65 billion in 2025 to USD 12.08 billion by 2031, at a CAGR of 7.9%.

MarketsandMarkets Logo

Browse through 250 market data tables and 80 figures spread across 300+ pages and the in-depth TOC on the "Contrast media Market - Global Forecast to 2031"

Contrast Media Market Size & Forecast:

  • Market Size Available for Years: 2025–2031
  • 2025 Market Size: USD 7.65 billion
  • 2031 Projected Market Size: USD 12.08 billion
  • CAGR (2025–2031): 7.9%

Contrast Media Market Trends & Insights:

  • By type, the iodinated contrast media segment is estimated to account for the highest market share of 55% in 2026.
  • By modality, the CT segment is expected to register the highest CAGR of 8.2%.
  • By indication, the cardiovascular disease segment is expected to dominate the market with 48.0% revenue share in 2026.
  • The Asia Pacific region is projected to witness the highest CAGR of 9.5% in the contrast media market.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911

The growing number of diagnostic imaging tests worldwide is a major driver of demand for contrast agents. There is a higher need for accurate and timely diagnoses due to the rising rates of mental health disorders, cancers, and heart disease. Additionally, an extra factor contributing to the growth in imaging procedures is the aging population, which is more vulnerable to chronic illnesses. Lastly, ongoing advances in imaging technology and improvements in the safety profiles of contrast agents continue to support the industry's growth.

By type, the iodinated contrast media segment is expected to register a significant growth rate over the forecast period of 2026-2031.

the contrast media market is segmented into iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barium-based contrast media. The iodinated contrast media segment had the highest CAGR in 2026. Since iodinated contrast media are commonly used in numerous CT, MRI, ultrasound, and mammography procedures in hospitals and diagnostic centers, it is expected to have the highest CAGR. The increasing use of this product is driven by its widespread clinical acceptance, high imaging performance, and compatibility with the latest CT technology. Ongoing product modifications aimed at reducing toxicity and enhancing patient safety are further boosting demand. Additionally, global demand for iodinated contrast agents is growing rapidly, fueled by the expansion of cardiac and vascular imaging.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=911

By route of administration, the oral route segment accounted for the largest share of the contrast media market by route of administration in 2026.

the contrast media market is segmented into intravascular, oral, rectal, and other routes. The oral route dominates the contrast media market because it is the most common method in gastrointestinal imaging procedures, mainly for examining the stomach, intestines, and other abdominal organs. It is preferred for its non-invasiveness, ease of use, and greater patient-friendliness compared to injectable options. Additionally, oral contrast agents help reduce the risk of side effects associated with intravenous agents. Furthermore, oral contrast agents are an affordable alternative and can be easily used for routine diagnostic scans, which explains their widespread use in healthcare centers.

By end user, the hospitals, clinics, and ambulatory surgery centers segment accounted for the largest share of the contrast media market, by end user, in 2026.

the contrast media market is divided into hospitals, clinics, ambulatory surgery centers, and diagnostic imaging centers. In 2026, hospitals, clinics, ambulatory surgery centers, and diagnostic imaging centers held the largest share of the contrast media market. These end users result from the high volume of diagnostic and interventional imaging procedures they perform daily. These institutions have advanced CT, MRI, and angiography equipment, which are seeing a higher proportion of contrast-mediated scans across various clinical specialties. Increased patient visits to emergency care and chronic disease management also contribute to steady demand from these end users.

The Asia Pacific market is expected to register the highest growth during the forecast period.

The Asia Pacific contrast media market is expected to experience the highest growth from 2026 to 2031. One of the main reasons is the rising healthcare expenditure and the ongoing improvement of diagnostic infrastructure in countries like China and India. Market growth is further supported by increased awareness of early disease detection and better access to advanced imaging facilities in semi-urban and rural areas. Additionally, factors such as a large patient population, supportive policies, the growth of the medical tourism industry, and the opening of new private hospitals and diagnostic centers are driving higher demand for contrast and enhanced imaging procedures.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=911

Top Companies in Contrast Media Market:

The Top Companies in Contrast Media Market include Bracco Imaging S.p.A. (Italy), Bayer AG (Germany), Guerbet (US), Lantheus Medical Imaging (US), GE HealthCare (US), Unijules Life Sciences Ltd. (India), J.B. Chemicals & Pharmaceuticals Limited (India), Sanochemia Pharmazeutika GmbH (Germany), Taejoon Pharm Co., Ltd. (South Korea), Jodas Expoim (India), iMax Diagnostic Imaging Limited (Ireland), YZJ Group (China), Beijing Beilu Pharmaceutical Co., Ltd. (China), and Livealth Biopharma Pvt. Ltd. (India) among others.

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

Related Reports:

MRI Systems Market - Global Forecast to 2030

Preclinical Imaging Market - Global Forecast to 2030

Contrast Media Injectors Market - Global Forecast to 2029

Diagnostic Imaging Market - Global Forecast to 2030

X-Ray Detectors Market - Global Forecast to 2030

About MarketsandMarkets™ 

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on TwitterLinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets™ INC.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/contrast-media-market-worth-12-08-billion-by-2031--marketsandmarkets-302715876.html

Other news

Semperit-Übernahmeofferte: Vorstand und Aufsichtsrat skizzieren Pro und Contra

04.05.2026

Die Semperit AG Holding hat ihre mit Spannung erwartete Stellungnahme zum freiwilligen Übernahmeangebot der B&C Holding Österreich GmbH vorgelegt – ohne eine klare Empfehlung für oder gegen die Annahme auszusprechen. In der am 4. Mai 2026 veröffentlichten Äußerung arbeitet der Vorstand die aus seiner Sicht wesentlichen Argumente beider Seiten heraus und beschreibt das Papier ausdrücklich als Orientierungshilfe für die Aktionärinnen und Aktionäre. Der Aufsichtsrat schließt sich der Analyse an und verzichtet ebenfalls auf eine eigene Annahme- oder Ablehnungsempfehlung.

Kern der Offerte ist ein Angebotspreis von 15,00 Euro je Aktie. Damit verbindet sich laut Semperit eine Prämie von 25,2% auf den unbeeinflussten Schlusskurs vom 17. März 2026, also den Kurs vor Bekanntgabe des Angebots. Der Vorstand verweist zudem darauf, dass der angebotene Preis über den historischen Durchschnittskursen der Semperit-Aktie liegt und Investoren einen Ausstieg ermöglicht, der nicht von der jeweils gegebenen Marktliquidität abhängt – ein Argument vor allem für Anteilseigner mit kurzfristigem Liquiditätsbedarf oder begrenztem Anlagehorizont.

Dem stellt das Management deutliche Vorbehalte gegenüber. So liegt der Angebotspreis nach der veröffentlichten Stellungnahme unter dem Buchwert von 20,20 Euro je Aktie. Außerdem verweisen Vorstand und Aufsichtsrat auf aktuelle Analystenschätzungen von bis zu 22,00 Euro je Aktie. Aus ihrer Sicht bildet die Offerte damit nicht das volle mittel- bis langfristige Wertsteigerungspotenzial des Unternehmens ab. Wer das Angebot annimmt, verzichtet zugleich auf mögliche zukünftige Ertragschancen, falls sich Geschäft und Marktumfeld günstiger entwickeln sollten.

Ob die Annahme wirtschaftlich sinnvoll ist, hänge daher maßgeblich von der individuellen Situation der Anleger ab, betont Semperit. Eine Rolle spielten insbesondere der persönliche Anschaffungspreis, der geplante Anlagehorizont, der eigene Liquiditätsbedarf und steuerliche Überlegungen, ebenso wie Erwartungen an die weitere Entwicklung des Unternehmens und der Märkte. Vorstand und Aufsichtsrat empfehlen den Aktionärinnen und Aktionären, ihre persönlichen Verhältnisse sorgfältig zu prüfen und bei Bedarf fachkundigen Rat einzuholen. Die vollständigen Äußerungen zum Angebot sind auf der Semperit-Website im Investor-Relations-Bereich abrufbar; der nächste wichtige Termin im Finanzkalender ist die Quartalsmitteilung am 13. Mai 2026.